Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant-Reference-Cited by-同舟云学术

Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant

Published:2022-08-31 Issue:4 Volume:10 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Dimeglio Chloé¹²^ORCID,Herin Fabrice³⁴,Da-Silva Isabelle¹,Gernigon Caroline³⁴,Porcheron Marion¹,Chapuy-Regaud Sabine¹²,Izopet Jacques¹²^ORCID

Affiliation:

1. CHU Toulouse, Hôpital Purpan, Virology Laboratory, Toulouse, France

2. INSERM UMR1291 – CNRS UMR5051, Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy), Toulouse, France

3. Occupational Diseases Department, Toulouse University Hospital, Toulouse, France

4. UMR1295, unité mixte INSERM - Université Toulouse III Paul Sabatier, Centre for Epidemiology and Research in Population Health Unit (CERPOP), Toulouse, France

Abstract

Recent studies showed that the neutralizing antibody titer is an important contributor to protection against SARS-CoV-2. With the emergence of new variants, the question arises of maintaining the neutralizing capacities of vaccines and/or of a past infection.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.02706-21

Reference32 articles.

1. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

2. Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta)

3. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

4. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

5. SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status — Los Angeles County, California, May 1–July 25, 2021

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study of the cellular and humoral immune responses to SARS-CoV-2 vaccination;Heliyon;2024-04

2. Clinical and laboratory considerations: determining an antibody-based composite correlate of risk for reinfection with SARS-CoV-2 or severe COVID-19;Frontiers in Public Health;2023-12-28

3. Clinico-epidemiological profile and outcome of infected health care workers during the three consecutive waves of COVID-19 pandemic: a longitudinal cohort study;Therapeutic Advances in Vaccines and Immunotherapy;2023-01

4. Post-vaccination SARS-CoV-2 antibody kinetics and protection duration against Omicron in elderly population;Journal of Infection;2022-12

5. Current immunoassays and detection of antibodies elicited by Omicron SARS‐CoV‐2 infection;Journal of Medical Virology;2022-10-17